



# Kent Academic Repository

Lim, Jenson, Coates, Christopher J., Seoane, Paula I., Garelnabi, Mariam, Taylor-Smith, Leanne M., Monteith, Pauline, Macleod, Camille L., Escaron, Claire J., Brown, Gordon D., Hall, Rebecca A. and and others (2018) *Characterizing the Mechanisms of Nonopsonic Uptake of Cryptococci by Macrophages*. *The Journal of Immunology*, 200 (10). pp. 3539-3546. ISSN 0022-1767.

## Downloaded from

<https://kar.kent.ac.uk/91840/> The University of Kent's Academic Repository KAR

## The version of record is available from

<https://doi.org/10.4049/jimmunol.1700790>

## This document version

Author's Accepted Manuscript

## DOI for this version

## Licence for this version

CC BY (Attribution)

## Additional information

## Versions of research works

### Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

### Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

## Enquiries

If you have questions about this document contact [ResearchSupport@kent.ac.uk](mailto:ResearchSupport@kent.ac.uk). Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our [Take Down policy](https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies) (available from <https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies>).

# Characterising the mechanisms of non-opsonic uptake of Cryptococci by macrophages

Jenson Lim\*, Christopher J. Coates†, Paula I Seoane¶, Mariam Garelnabi¶, Leanne M Taylor-Smith¶,

Pauline Monteith\*, Camille L Macleod\*, Claire J Escaron‡, Gordon D Brown§, Rebecca A Hall¶,

Robin C May¶

\*Biological and Environmental Sciences, University of Stirling, Bridge of Allan, Stirling FK9 4LA,

UK

¶Institute of Microbiology and Infection, School of Biosciences, University of Birmingham,

Birmingham B15 2TT, UK

§Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen

Fungal Group, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK

‡Protein Reference Unit, South West London Pathology, St. Georges Hospital, London SW17 0NH,

UK

†Department of Biosciences, College of Science, Swansea University, Swansea SA2 8PP, Wales UK

## CORRESPONDING AUTHOR

Jenson Lim ([jenson.lim@stir.ac.uk](mailto:jenson.lim@stir.ac.uk))

Tel : +44 1786 467821

Fax : +44 1786 467843

**RUNNING TITLE:** Uptake of *Cryptococcus* by phagocytes

**KEY WORDS:** Syk/Dectin/*Cryptococcus neoformans*/*Cryptococcus gattii*/phagocytosis

## SOURCE OF FUNDING

Work in the May Lab is supported by project MitoFun, funded by the European Research Council

under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement

26 No. 614562 and by a Wolfson Research Merit Award from the Royal Society (to RCM). GDB is  
27 supported by the Wellcome Trust (102705), Wellcome Trust Strategic Award in Medical Mycology  
28 and Fungal Immunology (097377) and the MRC Centre for Medical Mycology at the University of  
29 Aberdeen (MR/N006364/1). JL is supported by a start-up fund from the University of Stirling.

30

## 31 **ABSTRACT**

32 The pathogenic fungus *Cryptococcus* enters the human host via inhalation into the lung and is able to  
33 reside in a niche environment that is serum (opsonin) limiting. Little is known about the mechanism by  
34 which non-opsonic phagocytosis occurs via phagocytes in such situations. Using a combination of  
35 soluble inhibitors of phagocytic receptors and macrophages derived from knockout mice and human  
36 volunteers, we show that uptake of non-opsonised *Cryptococcus neoformans* and *Cryptococcus gattii*  
37 via the mannose receptor is dependent on macrophage activation by cytokines. However, while uptake  
38 of *C. neoformans* is via both dectin-1 and dectin-2, *C. gattii* uptake occurs largely via dectin-1.  
39 Interestingly, dectin inhibitors also blocked phagocytosis of unopsonised Cryptococci in wax moth  
40 (*Galleria mellonella*) larvae and partially protected the larvae from infection by both fungi, supporting  
41 a key role for host phagocytes in augmenting early disease establishment. Finally, we demonstrated that  
42 internalisation of non-opsonised Cryptococci is not accompanied by the nuclear translocation of NFκB  
43 or its concomitant production of proinflammatory cytokines such as TNFα. Thus, non-opsonised  
44 Cryptococci are recognised by mammalian phagocytes in a manner that minimises proinflammatory  
45 cytokine production and potentially facilitates fungal pathogenesis.

46

47

48

49

## 50 INTRODUCTION

51 *Cryptococcus neoformans* and *Cryptococcus gattii* are encapsulated human fungal pathogens that cause  
52 cryptococcosis in immunocompromised and, more rarely, immunocompetent individuals. Often found  
53 as free-living cells in soil and avian excreta, Cryptococci are not intrinsic human pathogens. However,  
54 Cryptococci become human pathogens because several defence mechanisms possessed by these fungi  
55 also act as virulence factors within a human or animal host (1), including the ability firstly, to survive  
56 and replicate within free-living soil amoeba and, secondly to evade clearance by the host immune  
57 system by hiding and persisting within macrophages (2, 3).

58 As Cryptococci enter hosts via inhalation into the lungs, they are detected and phagocytosed by  
59 resident alveolar macrophages (4). Phagocytosis is a multi-step process that sequentially involves  
60 receptor-mediated particle recognition, actin-driven uptake, phagosome maturation and particle  
61 clearance. It is critical during the early innate immune response to ensure the removal of  
62 microorganisms and apoptotic cells as well as subsequent priming of the adaptive immune response  
63 through the production and release of cytokines, such as Tumour Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) (5).

64 Phagocytosis of Cryptococci is typically inefficient unless they are opsonised (coated) by antibodies or  
65 complement proteins found in serum within the circulatory system. Interestingly, there is a lack of  
66 serum opsonins in the alveoli of the lungs, and so the initial uptake of *Cryptococcus* upon colonisation  
67 is most likely through a non-opsonised route (6).

68 Non-opsonic phagocytosis requires host cell phagocytic pattern recognition receptors (PRRs) to  
69 directly recognise fungal cell wall components (pathogen associated molecular patterns; PAMPs) (7)  
70 such as  $\beta$ -glucans or mannan polysaccharides, but the nature of this interaction for Cryptococci remains  
71 unknown. Here we show that non-opsonised *C. neoformans* and *C. gattii* enter macrophages in a Syk-  
72 dependent, mannose receptor-independent manner that involves the receptors Dectin-1 and Dectin-2.  
73 This differential uptake of *C. neoformans* and *C. gattii* corresponds to differential exposure of PAMPs  
74 found on the fungal cell wall. Phagocytic kinetics of macrophages and insect haemocytes in the

75 absence or presence of cellular receptor inhibitors were similar in response to fungal targets. Finally,  
76 we demonstrate that entry of *Cryptococcus* does not affect NFκB nuclear translocation or subsequent  
77 TNF-α release, highlighting the remarkably non-inflammatory capabilities of this organism.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

For Peer Review. Do not distribute. Destroy after use.

## 99 MATERIALS AND METHODS

### 100 Reagents

101 All reagents (e.g. heat-inactivated fetal bovine serum, FBS; Dulbecco's Modified Eagle's Medium  
102 (DMEM); L-glutamine; powdered yeast-extract peptone dextrose, YPD and phosphate buffered saline,  
103 PBS) were purchased from Sigma unless stated otherwise. Mouse macrophage- and Human  
104 granulocyte-macrophage- colony stimulating factors (mM-CSF, 130-094-129 and hGM-CSF, 130-093-  
105 862) were purchased from Miltenyi Biotec. Commercially sourced inhibitors tested included the Syk  
106 inhibiting plant metabolite, Piceatannol (527948, Calbiochem), the  $\beta$ -1,3-glucan from brown algae  
107 *Laminaria digitata*, Laminarin (L9634, Sigma) and mannan from *Saccharomyces cerevisiae* (M7504,  
108 Sigma).

109 The antibodies used in this study were rabbit anti-sheep red blood cells, IgG fraction (#55806, MP  
110 Biomedicals), rabbit anti-sheep red blood cells, IgM fraction (CL9000M, VH Bio/Cedarlane), rabbit  
111 anti-p65 NFkB monoclonal antibody (clone D14E12, #8242, NEB/Cell Signalling), rat anti- $\alpha$ M (clone  
112 5c6, MCA2289, Bio-Rad/AbD Serotec), rabbit anti-Phospho-Syk (Tyr525/526 in humans, Tyr519/520  
113 in mice, clone C87C1, #2710, NEB/Cell Signalling, a kind gift from Yotis Senis, University of  
114 Birmingham). Rhodamine-Phalloidin and Alexa Fluor conjugated secondary antibodies were purchased  
115 from Life Technologies and Calcofluor White from Sigma. Glucan-6-phosphate and mouse anti-  
116 cryptococcal capsule antibody (clone 18B7) were kind gifts from David Williams (East Tennessee  
117 State University) and Arturo Casadevall (Albert Einstein College of Medicine) respectively.

118

### 119 Mice

120 Mice devoid of specific PRRs (in C57BL/6 background) were published before (8, 9) and were housed  
121 under pathogen-free conditions in the registered animal facility at the University of Aberdeen. Mice  
122 were allocated to experimental groups on the basis of genotype and age-matching. All animal  
123 procedures were performed according to the protocols provided by the Animal, Welfare and Ethical

124 Review Body (AWERB) of the University of Aberdeen and is regulated by the UK Home Office's  
125 Animal (Scientific Procedures) Act of 1986 and European Directive 2010/63/EU.

126

#### 127 **Yeast and bacterial cell growth conditions**

128 *C. neoformans* strain H99, *C. gattii* strain R265, *Candida albicans* strains SC5314 were incubated in  
129 liquid YPD medium for 24hr (unless stated otherwise) at 25°C on a rotator at 20rev/min (or 37°C, 200  
130 rpm for *C. albicans*). *Escherichia coli* strain DH5α was incubated in Luria-Bertani broth for 16hr at  
131 37°C in a shaking incubator at 200rpm. Yeast cells were centrifuged at 3000g for 2.5min (or 6000g for  
132 1min for *E. coli*), washed three times in PBS and counted with a haemocytometer prior to use.

133

#### 134 **Mammalian cell growth conditions**

135 Cells from the murine macrophage-like cell line J774.A1 (American Type Culture Collection number  
136 TIB-67) were cultured in DMEM supplemented with 2mM L-glutamine and 10% heat-inactivated FBS  
137 at 37°C, 5% CO<sub>2</sub> (10). As required, macrophages were scrapped in PBS, counted and seeded (50 000  
138 per well) onto 13mm acid-washed glass coverslips and incubated for 24hr at 37°C, 5% CO<sub>2</sub> – prior to  
139 experimental use.

140 Macrophages devoid of specific PRRs were derived from mouse bone marrow. Bone marrows were  
141 flushed using a 21-gauge needle from the hind leg bones of either receptor knockout or litter-matched  
142 wild type mice. Monocytes were differentiated into macrophages with 20ng/ml macrophage-colony  
143 stimulating factor (M-CSF, Miltenyi Biotec) for 7 days.

144 Pooled peripheral blood mononuclear cells (PBMC) were isolated from whole blood from healthy  
145 volunteers using density gradient centrifugation with Ficoll-Paque (GE Healthcare). The mononuclear  
146 layer was collected and washed with PBS to remove platelets. Monocytes were purified by adherence  
147 to plastic in RPMI-1640 media supplemented with 5% heat-inactivated FBS, 2mM glutamine,  
148 100mg/ml streptomycin, 100units/ml penicillin at 37°C, 5% CO<sub>2</sub> for 1hr. Non-adherent cells were

149 removed with PBS and adherent cells differentiated into macrophages with 20ng/ml recombinant  
150 human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Miltenyi Biotec) for 7 days.  
151 This study was covered by the University of Birmingham's Science, Technology, Engineering and  
152 Mathematics Ethical Review Committee.

153

#### 154 **Phagocytic challenge**

155 Macrophages were serum starved for 2 – 16hr with serum-free medium at 37°C, 5% CO<sub>2</sub>. Where  
156 needed, inhibitors were added directly and left for a further 30min. Next, media was removed prior to  
157 fresh serum-free medium added containing either 1µg/ml 18B7 antibody (against cryptococcal capsule)  
158 or unopsonised targets at a multiplicity of infection (MOI) of either 10:1 or 20:1 for 20-180min at  
159 37°C, 5% CO<sub>2</sub>. Cells were washed three times with PBS to remove unbound yeast/bacteria cells and  
160 fixed in 4% paraformaldehyde for 10min at room temperature.

161

#### 162 ***Galleria mellonella* maintenance**

163 Larvae of the greater wax moth, *G. mellonella*, were sourced from Livefoods Direct (UK) and stored in  
164 wood shavings in the dark at 13°C. This study was covered by the University of Stirling's Animal,  
165 Welfare and Ethical Review Body (AWERB). Healthy larvae weighing between 0.2 and 0.4 g were  
166 used in all experiments. Larvae were inoculated with different concentrations of inhibitors via  
167 intrahaemocoel injection 1hr prior to infection with 1 million *C. neoformans* H99 per larva as described  
168 previously (11). Controls consisted of larvae that received a 20µl PBS inoculum. 3-5 larvae were used  
169 per treatment, with all treatments being performed on at least three independent occasions.

170 For phagocytosis, larvae were bled and haemolymph treated as previously described (12). Briefly,  
171 pooled haemolymph was mixed with 0.5ml PBS and added onto a 13mm coverslip in a 24-well plate.  
172 Haemocytes were centrifuged onto the coverslips for 10 min at 500 x g at room temperature (RT),



173 before washing 3 times with PBS to remove non-internalised yeasts. Cells were then fixed with 4%  
174 paraformaldehyde before permeabilisation and immunostained as described below. All determinations  
175 were performed on at least three independent occasions.

176

### 177 **Immunofluorescence and scoring**

178 Fixed cells on coverslips were permeabilised with 0.1% Triton-X-100 for 5 min (if necessary to  
179 identify internalised yeasts), washed with PBS and blocked with 0.5% bovine serum albumin (BSA) in  
180 PBS for 30 min. Appropriate primary antibodies (1:200 dilution) were added to cells, left for 30 min at  
181 room temperature, washed with PBS, and counter stained with the appropriate fluorophore-conjugated  
182 secondary antibody, along with Rhodamine-Phalloidin and Calcofluor White. Coverslips were then  
183 washed in PBS and distilled water before mounted in ProLong Gold antifade reagent (Life  
184 Technologies) and analysed by microscopy.

185 For counting of phagocytosed yeast/bacteria, **fixed but unpermeabilised cells on coverslips were**  
186 **stained with Calcofluor White to highlight the external yeasts.** Coverslips were analysed with a Nikon  
187 Eclipse Ti microscope under a 63x oil immersion objective. Between 5 – 10 fields of view of each  
188 coverslip were counted for number of macrophages and association of microbial cells. At least 100  
189 macrophages were observed for each cover-slip.

190 The enrichment in phosphorylated Syk at sites of yeast binding **and the translocation of p65 into the**  
191 **nucleus during NFκB activation were** studied and scored by the Nikon A1R confocal microscope using  
192 20x – 63x objectives. For the former, a minimum of 25 infected cells per condition were analysed for a  
193 discrete local enrichment in marker signal (Syk) at bound particles. **For the latter, between 3-5 fields of**  
194 **view for each sample/coverslip were counted for the number of macrophages with p65 marker signal**  
195 **located within the nucleus and expressed as a percentage of the total number of macrophages (%NFκB**  
196 **nuclear translocation).**

197

198 ***In vitro* cytokine production**

199 J774.A1 and primary human macrophages were cultured in 96-well microtiter plates (Greiner) at 10000  
200 cells/well, in a final volume of 200µl. Cells were stimulated with either control medium or LPS or a  
201 range of unopsonised pathogenic yeasts. After 6hr of incubation at 37°C, plates were centrifuged (500g  
202 for 10min), and the supernatant was collected and stored at -80°C until cytokine assays were  
203 performed. Levels of TNF-α were determined by commercial ELISA kits, used according to the  
204 instructions of the manufacturer (R&D Systems).

205

206 **Statistical analyses**

207 Analysis carried out on the results described in this paper was by a generalise linear model (GLM)  
208 using a Poisson error distribution in R (R Development Core Team). This was tested for significance  
209 using a Posthoc Tukey Honesty Significant Difference (HSD) test.

210

211 **RESULTS**

212 **Uptake of non-opsonised Cryptococci via mannose receptor is activation dependent**

213 As previously observed, the levels of non-opsonic uptake of Cryptococci is very low (e.g. 0.4% of *C.*  
214 *neoformans* serotype D was taken up by unstimulated mouse peritoneal macrophages; or 7-21% of *C.*  
215 *gattii* R265 was taken up by human dendritic cells; **13, 14**) and our results are in agreement with those  
216 findings – 8.89% or 5.83% of primary human macrophages contained one or more *C. neoformans* H99,  
217 or *C. gattii* R265, respectively (based on the carrier controls in **Figures 1C** and **2B**) after two hours of  
218 incubation. The mannose receptor is broadly expressed on macrophages and important for the non-  
219 opsonic uptake of fungal pathogens such as *Candida albicans* and *Pneumocystis carinii* (**15, 16**). The  
220 uptake of *C. neoformans* H99, or *C. gattii* R265 by J774.A1 macrophages pre-treated with soluble

221 mannan (a competitive inhibitor of mannose receptor binding) was unaltered relative to control  
222 (untreated) cells (**Figure 1A**). Similarly, M-CSF differentiated bone marrow macrophages from  
223 mannose receptor knock-out mice (MR KO) showed no reduction in uptake of either *Cryptococcus*  
224 *neoformans* (Cn) or *Cryptococcus gattii* (Cg) relative to wildtype control cells (**Figure 1B**).

225 Interestingly, however, GM-CSF differentiated primary human macrophages showed a strong  
226 inhibition of uptake under the same conditions (**Figure 1C**), suggesting that the mannose receptor may  
227 play a greater role in cryptococcal uptake into human cells than those of mice.

228

### 229 **Phagocytosis of unopsonised Cryptococci is Syk-dependent**

230 The other major class of non-opsonic phagocytic receptors for fungi are the dectins (**17**). Both dectin-1  
231 and dectin-2 require Syk activity for their function, via immunoreceptor tyrosine-based activation  
232 motifs (ITAM) contained within dectin-1 itself or via membrane association with ITAM-containing Fc  
233 receptor  $\gamma$  chain in the case of dectin-2 (**18**). Inhibiting Syk activity in J774.A1 cells by using  
234 piceatannol (**19**) resulted in a marked reduction in their ability to phagocytose either *C. neoformans*  
235 H99 or *C. gattii* R265 (**Figure 2A**,  $p < 0.05$ ). The same observation was also seen in GM-CSF  
236 differentiated primary human macrophages from pooled monocytes isolated from human volunteers  
237 (**Figure 2B**). In line with this, staining with an anti-Phospho-Syk antibody showed intense  
238 accumulation of active Syk at phagocytic cups forming around non-opsonised Cryptococci (**Figure 3**).  
239 This antibody was raised against the tyrosine phosphorylated residues at positions 525 and 526, located  
240 in the activation loop of the Syk kinase domain and essential for Syk function (**20**). Therefore, we  
241 propose that the localisation of this antibody to the sites of non-opsonic uptake of Cryptococci and the  
242 activity of piceatannol in blocking uptake suggests that Syk activity is required for internalisation.

243

### 244 **Phagocytosis of unopsonised Cryptococci is partially dependent on Dectin-1**

245 To test for a role for the dectin family of receptors during phagocytic uptake of non-opsonised  
246 *Cryptococci*, we first exposed J774.A1 macrophages (Figure 4A) or differentiated primary human  
247 macrophages (Figure 4B) to the dectin-1 inhibitor glucan-6-phosphate before challenging with either  
248 unopsonised *C. gattii* R265 or *C. neoformans* H99. This inhibitor partially blocked the uptake of both  
249 species of *Cryptococcus*, suggesting dectin-1 contributes towards *Cryptococci* uptake but is not the sole  
250 recognition receptor involved in this process (Figures 4A and 4B). In line with this, M-CSF-  
251 differentiated bone marrow macrophages (BMM) from dectin-1 and dectin-2 knockout mice both  
252 showed substantially impaired uptake of *C. neoformans* H99 – surprisingly, this was not the case for *C.*  
253 *gattii* R265 (Figure 4C). This suggests either the presence of another Syk-dependent non-opsonic  
254 receptor, or that both dectins are redundant with each other for *C. gattii*, but not *C. neoformans* uptake.

255

#### 256 **Non-opsonic uptake in the *Galleria* model**

257 The greater wax moth, *Galleria mellonella*, is widely used as a model organism in the study of host-  
258 pathogen interactions with a variety of human pathogens (21). As with other insects, *G. mellonella* does  
259 not possess an adaptive immune system like mammals but possesses a complex innate immune system  
260 that includes phagocytic cells, termed haemocytes (22, 23). We therefore tested whether non-opsonic  
261 uptake of *Cryptococci* in *G. mellonella* showed similar receptor dependency as in mammalian cells by  
262 pre-treating larvae for 1hr with soluble mannan or glucan-6-phosphate or laminarin. The full genome  
263 sequence of *Galleria* is currently available though not fully annotated (24). However, several  $\beta$ -1,3-  
264 glucan binding protein analogues and C-type lectins have been characterised in this species, as well as  
265 other Lepidoptera, namely *Manduca sexta* (25, 26), *Bombyx mori* (27) and *Plodia interpunctella*  
266 (28). Recognition of fungal PAMPs (e.g. curdlan and mannan) by membrane bound receptors modulate  
267 cellular (haemocyte)-directed immunity in insects (encapsulation, nodulation and phagocytosis) (29).  
268 Whilst soluble mannan did not significantly reduce association of *Cryptococci* with *Galleria*

269 haemocytes in data presented here, both glucan-6-phosphate and laminarin led to a marked reduction in  
270 uptake (Figure 5,  $p < 0.001$  for both when compared to the PBS controls).

271 Interestingly, administering glucan-6-phosphate or laminarin for 24 h appeared to partially protect the  
272 insect larvae from infection by both unopsonised species of *Cryptococcus* (Figure 6) suggesting that  
273 disease establishment in this model organism requires the fungus to grow intracellularly, something  
274 that has previously been proposed for human hosts (30).

275

### 276 **Cryptococcal uptake by macrophages does not lead to increased proinflammatory cytokine** 277 **secretion**

278 Unlike many pathogens, internalisation of opsonised Cryptococci into phagocytes is not accompanied  
279 by the production of proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin  
280 (IL)-1 $\alpha$  or IL-1 $\beta$  (31, 32). To test whether this is also true of non-opsonic uptake, we measured the  
281 secretion of TNF $\alpha$  and nuclear translocation of p65 (a major regulator of cytokine transcription) from  
282 J774.A1 macrophages upon challenge with unopsonised or serum-opsonised *C. neoformans* H99 or *C.*  
283 *gattii* R265. Although LPS-stimulated macrophages showed strong nuclear translocation of p65,  
284 neither IgG-opsonised nor unopsonised *C. neoformans* H99 or *C. gattii* R265 stimulated NF $\kappa$ B  
285 activation (Figure 7A). However, NF $\kappa$ B activation could be restored in cryptococcal exposed  
286 macrophages by the subsequent addition of LPS (Figure 7B).

287 Furthermore, to test whether internalisation of unopsonised Cryptococci into J774.A1 mouse  
288 macrophages or primary human macrophages elicits the production of proinflammatory cytokines such  
289 as tumor necrosis factor (TNF), we measured the secretion of TNF $\alpha$  from J774.A1 macrophages or  
290 primary human macrophages upon challenge with unopsonised *C. neoformans* H99 or *C. gattii* R265,  
291 with *Candida albicans* and LPS as controls. With J774.A1 mouse macrophage and primary human  
292 macrophages, *C. albicans*- or LPS- stimulated macrophages showed stronger TNF $\alpha$  production

293 compared to varying doses of *C. neoformans* H99 or *C. gattii* R265 (Figure 8;  $p = 0.04$  for Ca vs.  
294 media control,  $p > 0.05$  for Ca vs. Cn/Cg). Overall this suggests that Cryptococci do not actively block  
295 inflammatory signalling in host cells, and do not induce a strong inflammatory stimulus following non-  
296 opsonic uptake.

297

## 298 DISCUSSION

299 In this study, we examined the phagocytic uptake of unopsonised cryptococcal yeast particles by  
300 macrophages. This process relies on the use of phagocytic receptors, which can be categorised either as  
301 opsonic or non-opsonic. Opsonic phagocytic receptors include the Fc receptor and complement  
302 receptor families, which recognises antibody- or complement- opsonised (coated) particles,  
303 respectively. Non-opsonic phagocytic receptors are pattern recognition receptors (PRRs), such as the  
304 C-type lectin family of receptors recognizes distinct pathogen-associated molecular patterns (PAMPs)  
305 on the fungal surface (33).

306 While phagocytosis of *Cryptococcus* within the circulatory system would occur predominantly through  
307 an opsonised (coated) uptake route due to the presence of antibodies and/or complement proteins found  
308 in serum, this is not always the case. For example, first encounter of the human body with  
309 *Cryptococcus* is through the lungs when desiccated yeast cells or spores are breathed in. These  
310 cryptococcal particles encounter their initial immunological challenge through resident alveolar  
311 macrophages and dendritic cells in a serum-deficient or low-serum environment (34, 35, 36).

312 Interestingly, it was reported recently that between 25-40% of mouse lung-resident macrophages are  
313 able to phagocytose *C. neoformans* particles through a scavenger receptor pathway (37). Therefore, this  
314 confirms that initial uptake of *Cryptococcus* by macrophages is most likely through a non-opsonised  
315 route and there is a need to understand the mechanisms that underpins this process (6). We confirmed  
316 that, compared to the bacterium *Escherichia coli* or fungus *Candida albicans*, Cryptococci cells are not  
317 readily taken up by mammalian macrophages, most likely due to the presence of the capsule which

318 renders *Cryptococci* anti-phagocytic (38, 39). By using a combination of a soluble mannose inhibitor  
319 and mannose receptor knockout mouse tissue, we demonstrated that mannose receptor was not  
320 necessary for the uptake of either species of *Cryptococcus*, in line with recent data from the zebrafish  
321 model (40), though this is not the case in primary human macrophages. We note that others have shown  
322 mannose receptor knockout mice to be more susceptible to *C. neoformans* (41) and demonstrated a role  
323 for this receptor, along with Fc $\gamma$ RII (CD32) in driving cryptococcal uptake into dendritic cells (42).  
324 Thus, mannose receptor dependency apparently varies across different cell types and tissue contexts.  
325 Next, we pursued a different set of non-opsonic pattern recognition receptors, dectin-1 and dectin-2  
326 which are C-type lectin receptors (CLRs) that are highly expressed in macrophages and are key  $\beta$ -  
327 glucan receptors (43, 44). Recognition of soluble or surface expressed  $\beta$ -glucans on yeasts is sufficient  
328 to initiate and mediate phagocytosis and pro-inflammatory cytokine responses (45). Both of these  
329 receptors require Syk activity (46, 47, 18) and indeed our data clearly demonstrate the activation of Syk  
330 at phagocytic cups containing unopsonised *Cryptococci*, as well as a strong dependency on Syk for  
331 particle uptake. Interestingly, pharmacological inhibition of dectins inhibited uptake of both *C.*  
332 *neoformans* and *C. gattii* in J774.A1 mouse and human macrophages, but bone marrow macrophages  
333 (BMM) from dectin-1- and dectin-2- knockout mice showed defects only in the uptake of *C.*  
334 *neoformans* and not *C. gattii*, an effect that has been observed before (48). The most parsimonious  
335 explanation is therefore that the two dectin receptors are redundant for the uptake of *C. gattii*, but not  
336 *C. neoformans*, perhaps reflecting differing the surface components between the two species as  
337 reported recently (49). Such surface variation between species, strains and potentially developmental  
338 stages of *Cryptococci* may explain many of the previous inconsistencies in the literature regarding  
339 dectin dependency (or otherwise) (50, 51).  
340 Alongside mouse macrophages, we adopted wax worm larvae (*Galleria mellonella*) as an alternative  
341 model for understanding cryptococcal virulence and host immune responses (52 – 54) in which

342 cryptococcal phagocytosis has previously been reported (55). Our data demonstrate striking similarities  
343 in patterns of uptake between this invertebrate host and murine phagocytes. In addition, we showed  
344 that inhibiting phagocytosis in this alternative host reduces disease burden, highlighting the importance  
345 of host phagocytes as a niche for cryptococcal replication.

346 We acknowledge that while there are currently no direct dectin receptor homologues identified in *G.*  
347 *mellonella*, many C-type lectins have been characterised in other insect models, for example the  
348 tobacco hornworm, *Manduca sexta* (immulectin-2 facilitates phagocytosis of bacteria; 56), webworm,  
349 *Hyphantria cunea* (lectin; 57, 58) silkworm, *Bombyx mori* (BmLBP and BmMBP; 59, 60) and the  
350 cockroach, *Blaberus discoidalis* (a  $\beta$ -glucan-specific lectin; 61). These invertebrate C-type lectins show  
351 up to 35% similarity with mammalian C-type lectins and can bind to several PAMPs, including LPS,  
352 LTA and  $\beta$ -glucan and are inducible when the host is exposed to microbial challenge or ligands and the  
353 mechanisms for uptake of pathogenic microbes by *G. mellonella* hemocytes are similar to that of  
354 human neutrophils (62).

355 Two key reports have shown that there are at least 3 scavenger receptors involved in the recognition of  
356 different serotypes of *Cryptococcus neoformans*, namely the homologous genes from the nematode  
357 *Caenorhabditis elegans*, CED-1 and C03F11.3 as well as the mouse MARCO scavenger receptors (37,  
358 63). Interestingly, knocking out MARCO gene from mice did not abolish uptake of *Cryptococcus*  
359 *neoformans* by lung-resident mononuclear phagocytes (37), suggesting role(s) for the extent and  
360 distribution of multiple receptors and ligands on the surface of both host cell and yeast.

361 Finally, we demonstrate that entry of *Cryptococcus* does not affect NF $\kappa$ B nuclear translocation and its  
362 subsequent TNF- $\alpha$  release in the Dectin-1/Syk/NF $\kappa$ B signalling axis – both in J774.A1 mouse  
363 macrophages and in primary human macrophages. Although it is known that Dectin-1 coupling to Syk  
364 leads to downstream activation of NF $\kappa$ B, which coordinate the transcription of innate response genes



365 including expression of proinflammatory cytokines such as TNF- $\alpha$  (64-66), this appears not to be the  
366 case for cryptococcal uptake.

367 In conclusion, we propose that unopsonised Cryptococci are recognised and engulfed via mannose  
368 receptor- or dectin-based recognition *in vitro* depending on the activation state of the host cells. The  
369 absence of an associated pro-inflammatory cascade allows the yeast to exploit this intracellular niche  
370 for rapid disease establishment.

371

## 372 ACKNOWLEDGEMENTS

373 We thank Neil Hotchin, Yotis Senis, David Williams and Arturo Casadevall for sharing reagents and  
374 members of the Krachler/Voelz/Hall/May lab for helpful scientific discussions as well as Charles Eliot  
375 Timothy Paine for his assistance with the statistical analysis. JL would like to thank his family for their  
376 help and support during the writing of this manuscript.

377

## 378 REFERENCES

- 379 1. Idnurm, A., Y. S. Bahn, K. Nielsen, X. Lin, J. A. Fraser, and J. Heitman. 2005. Deciphering the  
380 model pathogenic fungus *Cryptococcus neoformans*. *Nat. Rev. Microbiol.* 10: 753-764.
- 381 2. Steenbergen J. N., H. A. Shuman, and A. Casadevall. 2001. *Cryptococcus neoformans*  
382 interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic  
383 strategy in macrophages. *Proc. Natl. Acad. Sci. U S A.* 98: 15245-15250.
- 384 3. Feldmesser, M., S. Tucker, and A. Casadevall. 2001. Intracellular parasitism of macrophages by  
385 *Cryptococcus neoformans*. *Trends Microbiol.* 9: 273-278.
- 386 4. Fan, W., P. R. Kraus, M. J. Boily, and J. Heitman. 2005. *Cryptococcus neoformans* gene  
387 expression during murine macrophage infection. *Eukaryot. Cell.* 4: 1420-1433.
- 388 5. Flannagan, R. S., V. Jaumouillé, and S. Grinstein. 2012. The cell biology of phagocytosis.  
389 *Annu. Rev. Pathol.* 7: 61-98.

- 390 6. Walenkamp, A. M., J. Scharringa, F. M. Schramel, F. E. Coenjaerts, and I. M. Hoepelman.  
391 2000. Quantitative analysis of phagocytosis of *Cryptococcus neoformans* by adherent  
392 phagocytic cells by fluorescence multi-well plate reader. *J. Microbiol. Methods*. 40: 39-45.
- 393 7. Johnston, S. A., and R. C. May. 2013. *Cryptococcus* interactions with macrophages: evasion  
394 and manipulation of the phagosome by a fungal pathogen. *Cell Microbiol*. 15: 403-411.
- 395 8. Taylor, P. R., S. V. Tsoni, J. A. Willment, K. M. Dennehy, M. Rosas, H. Findon, K. Haynes, C.  
396 Steele, M. Botto, S. Gordon, et al. 2007. Dectin-1 is required for beta-glucan recognition and  
397 control of fungal infection. *Nat. Immunol*. 8:31-38.
- 398 9. Ifrim, D. C., J. M. Bain, D. M. Reid, M. Oosting, I. Verschueren, N. A. Gow, J. H. van Krieken,  
399 G. D. Brown, B. J. Kullberg, L. A. Joosten, et al. 2014. Role of Dectin-2 for host defense  
400 against systemic infection with *Candida glabrata*. *Infect. Immun*. 82: 1064-1073.
- 401 10. Caron, E., and A. Hall. 1998. Identification of two distinct mechanisms of phagocytosis  
402 controlled by different Rho GTPases. *Science*. 282: 1717-1721.
- 403 11. Mowlds, P., C. Coates, J. Renwick, and K. Kavanagh. 2010. Dose-dependent cellular and  
404 humoral responses in *Galleria mellonella* larvae following beta-glucan inoculation. *Microbes*  
405 *Infect*. 12: 146-153.
- 406 12. Harding, C. R., G. N. Schroeder, J. W. Collins, and G. Frankel. 2013. Use of *Galleria*  
407 *mellonella* as a model organism to study *Legionella pneumophila* infection. *J. Vis. Exp*. 81:  
408 e50964.
- 409 13. Kozel, T. R., and E. C. Gotschlich. 1982. The capsule of *Cryptococcus neoformans* passively  
410 inhibits phagocytosis of the yeast by macrophages. *J. Immunol*. 129: 1675-1680.
- 411 14. Huston, S. M., P. Ngamskulrungrroj, R. F. Xiang, H. Ogbomo, D. Stack, S. S. Li, M. Timm-  
412 McCann, S. K. Kyei, P. Oykhman, K. J. Kwon-Chung, and C. H. Mody. 2016. *Cryptococcus*  
413 *gattii* Capsule Blocks Surface Recognition Required for Dendritic Cell Maturation Independent  
414 of Internalization and Antigen Processing. *J. Immunol*. 196: 1259-1271.

- 415 **15.** Porcaro, I., M. Vidal, S. Jouvert, P. D. Stahl, and J. Giaimis. 2003. Mannose receptor  
416 contribution to *Candida albicans* phagocytosis by murine E-clone J774 macrophages. *J. Leukoc.*  
417 *Biol.* 74: 206-215.
- 418 **16.** Ezekowitz, R. A., D. J. Williams, H. Koziel, M. Y. Armstrong, A. Warner, F. F. Richards, and  
419 R. M. Rose. 1991. Uptake of *Pneumocystis carinii* mediated by the macrophage mannose  
420 receptor. *Nature.* 351: 155-158.
- 421 **17.** Drummond, R. A., and G. D. Brown. 2011. The role of Dectin-1 in the host defence against  
422 fungal infections. *Curr. Opin. Microbiol.* 14: 392-399
- 423 **18.** Saijo, S., and Y. Iwakura. 2011. Dectin-1 and Dectin-2 in innate immunity against fungi. *Int.*  
424 *Immunol.* 23:467-472.
- 425 **19.** Oliver, J. M., D. L. Burg, B. S. Wilson, J. L. McLaughlin, and R. L. Geahlen. 1994. Inhibition  
426 of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective  
427 inhibitor, piceatannol. *J. Biol. Chem.* 269: 29697-29703.
- 428 **20.** Zhang, J., M. L. Billingsley, R. L. Kincaid, and R. P. Siraganian. 2000. Phosphorylation of Syk  
429 activation loop tyrosines is essential for Syk function. An in vivo study using a specific anti-  
430 Syk activation loop phosphotyrosine antibody. *J. Biol. Chem.* 275: 35442-35447.
- 431 **21.** Desbois, A. P., and S. McMillan. 2015. Paving the way to acceptance of *Galleria mellonella* as  
432 a new model insect. *Virulence.* 6: 410-411.
- 433 **22.** Butt, T. M., C. J. Coates, I. M. Dubovskiy, and N. A. Ratcliffe. 2016. Entomopathogenic Fungi:  
434 New Insights into Host-Pathogen Interactions. *Adv. Genet.* 94: 307-364.
- 435 **23.** Mukherjee, K., R. Raju, R. Fischer, and A. Vilcinskas. 2013. *Galleria mellonella* as a model  
436 host to study gut microbe homeostasis and brain infection by the human pathogen *listeria*  
437 *monocytogenes*. *Adv. Biochem. Eng. Biotechnol.* 135: 27-39.
- 438 **24.** Lange, A., S. Beier, D. H. Huson, R. Parusel, F. Iglauer, and J. S. Frick. 2018. Genome  
439 Sequence of *Galleria mellonella* (Greater Wax Moth). *Genome Announc.* 6: e01220-17.

- 440 **25.** Yu, X. Q., H. Gan, and M. R. Kanost. 1999. Immulectin, an inducible C-type lectin from an  
441 insect, *Manduca sexta*, stimulates activation of plasma prophenol oxidase. *Insect Biochem. Mol.*  
442 *Biol.* 29: 585-597.
- 443 **26.** Ma, C., and M. R. Kanost. 2000. A beta1,3-glucan recognition protein from an insect, *Manduca*  
444 *sexta*, agglutinates microorganisms and activates the phenoloxidase cascade. *J. Biol. Chem.*  
445 275: 7505-7514.
- 446 **27.** Ochiai, M., and M. Ashida. 2000. A pattern-recognition protein for beta-1,3-glucan. The  
447 binding domain and the cDNA cloning of beta-1,3-glucan recognition protein from the  
448 silkworm, *Bombyx mori*. *J. Biol. Chem.* 275: 4995-5002.
- 449 **28.** Fabrick, J. A., J. E. Baker, and M. R. Kanost. 2003. cDNA cloning, purification, properties, and  
450 function of a beta-1,3-glucan recognition protein from a pyralid moth, *Plodia interpunctella*.  
451 *Insect Biochem. Mol. Biol.* 33: 579-594.
- 452 **29.** Whitten, M. M., I. F. Tew, B. L. Lee, and N. A. Ratcliffe. 2004. A novel role for an insect  
453 apolipoprotein (apolipoprotein III) in beta-1,3-glucan pattern recognition and cellular  
454 encapsulation reactions. *J. Immunol.* 172: 2177-2185.
- 455 **30.** Alvarez, M., T. Burn, Y. Luo, L. A. Pirofski, and A. Casadevall. 2009. The outcome of  
456 *Cryptococcus neoformans* intracellular pathogenesis in human monocytes. *BMC Microbiol.* 9:  
457 51.
- 458 **31.** Cross, C. E., and G. J. Bancroft. 1995. Ingestion of acapsular *Cryptococcus neoformans* occurs  
459 via mannose and beta-glucan receptors, resulting in cytokine production and increased  
460 phagocytosis of the encapsulated form. *Infect. Immun.* 63: 2604-2611.
- 461 **32.** Netea, M. G., R. J. Stuyt, S. H. Kim, J. W. Van der Meer, B. J. Kullberg, and C. A. Dinarello.  
462 2002. The role of endogenous interleukin (IL)-18, IL-12, IL-1beta, and tumor necrosis factor-  
463 alpha in the production of interferon-gamma induced by *Candida albicans* in human whole-  
464 blood cultures. *J. Infect. Dis.* 18: 963-970.

- 465 **33.** Goodridge, H. S., A. J. Wolf, and D. M. Underhill. 2009. Beta-glucan recognition by the innate  
466 immune system. *Immunol. Rev.* 230: 38-50.
- 467 **34.** Lee, S. C., Y. Kress, M. L. Zhao, D. W. Dickson, and A. Casadevall. 1995. Cryptococcus  
468 neoformans survive and replicate in human microglia. *Lab. Invest.* 73: 871-879.
- 469 **35.** Feldmesser, M., Y. Kress, P. Novikoff, and A. Casadevall. 2000. Cryptococcus neoformans is a  
470 facultative intracellular pathogen in murine pulmonary infection. *Infect. Immun.* 68: 4225-4237.
- 471 **36.** Velagapudi, R, Y. P. Hsueh, S. Geunes-Boyer, J. R. Wright, and J. Heitman. 2009. Spores as  
472 infectious propagules of Cryptococcus neoformans. *Infect. Immun.* 77: 4345-4355.
- 473 **37.** Xu, J., A. Flaczyk, L. M. Neal, Z. Fa, A. J. Eastman, A. N. Malachowski, D. Cheng, B. B.  
474 Moore, J. L. Curtis, J. J. Osterholzer, et al. 2017. Scavenger Receptor MARCO Orchestrates  
475 Early Defenses and Contributes to Fungal Containment during Cryptococcal Infection. *J.*  
476 *Immunol.* 198: 3548-3557.
- 477 **38.** Levitz, S. M., and D. J. DiBenedetto. 1989. Paradoxical role of capsule in murine  
478 bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. *J. Immunol.* 142:  
479 659-665.
- 480 **39.** Del Poeta, M. 2004. Role of phagocytosis in the virulence of Cryptococcus neoformans.  
481 *Eukaryot. Cell.* 3: 1067-1075.
- 482 **40.** Bojarczuk, A., K. A. Miller, R. Hotham, A. Lewis, N. V. Ogryzko, A. A. Kamuyango, H. Frost,  
483 R. H. Gibson, E. Stillman, R. C. May, et al. 2016. Cryptococcus neoformans Intracellular  
484 Proliferation and Capsule Size Determines Early Macrophage Control of Infection. *Sci. Rep.* 6:  
485 21489.
- 486 **41.** Dan, J. M., R. M. Kelly, C. K. Lee, and S. M. Levitz. 2008. Role of the mannose receptor in a  
487 murine model of Cryptococcus neoformans infection. *Infect. Immun.* 76: 2362-2367.

- 488 **42.** Syme, R. M., J. C. Spurrell, E. K. Amankwah, F. H. Green, and C. H. Mody. 2002. Primary  
489 dendritic cells phagocytose *Cryptococcus neoformans* via mannose receptors and Fcγ  
490 receptor II for presentation to T lymphocytes. *Infect. Immun.* 70: 5972-5981.
- 491 **43.** Brown, G. D., P. R. Taylor, D. M. Reid, J. A. Willment, D. L. Williams, L. Martinez-Pomares,  
492 S. Y. Wong, and S. Gordon. 2002. Dectin-1 is a major beta-glucan receptor on macrophages. *J.*  
493 *Exp. Med.* 196: 407-412.
- 494 **44.** Kerscher, B., J. A. Willment, and G. D. Brown. 2013. The Dectin-2 family of C-type lectin-like  
495 receptors: an update. *Int. Immunol.* 25: 271-277.
- 496 **45.** Brown, G. D. 2006. Dectin-1: a signalling non-TLR pattern-recognition receptor. *Nat. Rev.*  
497 *Immunol.* 6: 33-43.
- 498 **46.** Rogers, N. C., E. C. Slack, A. D. Edwards, M. A. Nolte, O. Schulz, E. Schweighoffer, D. L.  
499 Williams, S. Gordon, V. L. Tybulewicz, G. D. Brown, and C. Reis e Sousa. 2005. Syk-  
500 dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C  
501 type lectins. *Immunity.* 22: 507-517.
- 502 **47.** Underhill, D. M., E. Rosnagle, C. A. Lowell, and R. M. Simmons. 2005. Dectin-1 activates  
503 Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. *Blood.*  
504 106: 2543-2550.
- 505 **48.** Nakamura, K., T. Kinjo, S. Saijo, A. Miyazato, Y. Adachi, N. Ohno, J. Fujita, M. Kaku, Y.  
506 Iwakura, and K. Kawakami. 2007. Dectin-1 is not required for the host defense to *Cryptococcus*  
507 *neoformans*. *Microbiol. Immunol.* 51: 1115-1119.
- 508 **49.** Benaducci, T., C. Sardi Jde, N. M. Lourencetti, L. Scorzoni, F. P. Gullo, S. A. Rossi, J. B.  
509 Derissi, M. C. de Azevedo Prata, A. M. Fusco-Almeida, and M. J. Mendes-Giannini. 2016.  
510 Virulence of *Cryptococcus* sp. Biofilms In Vitro and In Vivo using *Galleria mellonella* as an  
511 Alternative Model. *Front. Microbiol.* 7: 290.

- 512 **50.** Giles, S. S., T. R. Dagenais, M. R. Botts, N. P. Keller, and C. M. Hull. 2009. Elucidating the  
513 pathogenesis of spores from the human fungal pathogen *Cryptococcus neoformans*. *Infect.*  
514 *Immun.* 77: 3491-3500.
- 515 **51.** Walsh, N. M., M. Wuthrich, H. Wang, B. Klein, and C. M. Hull. 2017. Characterization of C-  
516 type lectins reveals an unexpectedly limited interaction between *Cryptococcus neoformans*  
517 spores and Dectin-1. *PLoS One.* 12: e0173866.
- 518 **52.** Firacative, C., S. Duan, and W. Meyer. 2014. *Galleria mellonella* model identifies highly  
519 virulent strains among all major molecular types of *Cryptococcus gattii*. *PLoS One.* 9: e105076.
- 520 **53.** Eisenman, H. C., R. Duong, H. Chan, R. Tsue, and E. E. McClelland. 2014. Reduced virulence  
521 of melanized *Cryptococcus neoformans* in *Galleria mellonella*. *Virulence.* 5: 611-618.
- 522 **54.** Mylonakis, E., R. Moreno, J. B. El Khoury, A. Idnurm, J. Heitman, S. B. Calderwood, F. M.  
523 Ausubel, and A. Diener. 2005. *Galleria mellonella* as a model system to study *Cryptococcus*  
524 *neoformans* pathogenesis. *Infect. Immun.* 73: 3842-3850.
- 525 **55.** García-Rodas, R., A. Casadevall, J. L. Rodríguez-Tudela, M. Cuenca-Estrella, and O. Zaragoza.  
526 2011. *Cryptococcus neoformans* capsular enlargement and cellular gigantism during *Galleria*  
527 *mellonella* infection. *PLoS One.* 6: e24485.
- 528 **56.** Yu, X. Q., and M. R. Kanost. 2004. Immulectin-2, a pattern recognition receptor that stimulates  
529 hemocyte encapsulation and melanization in the tobacco hornworm, *Manduca sexta*. *Dev.*  
530 *Comp. Immunol.* 28: 891-900.
- 531 **57.** Shin, S. W., D. S. Park, S. C. Kim, and H. Y. Park. 2000. Two carbohydrate recognition  
532 domains of *Hyphantria cunea* lectin bind to bacterial lipopolysaccharides through O-specific  
533 chain. *FEBS Lett.* 467: 70-74.
- 534 **58.** Shin, S. W., S. S. Park, D. S. Park, M. G. Kim, S. C. Kim, P. T. Brey, and H. Y. Park. 1998.  
535 Isolation and characterization of immune-related genes from the fall webworm, *Hyphantria*

- 536 cunea, using PCR-based differential display and subtractive cloning. *Insect Biochem. Mol. Biol.*  
537 28: 827-37.
- 538 **59.** Koizumi, N., M. Imamura, T. Kadotani, K. Yaoi, H. Iwahana, and R. Sato. 1999. The  
539 lipopolysaccharide-binding protein participating in hemocyte nodule formation in the silkworm  
540 *Bombyx mori* is a novel member of the C-type lectin superfamily with two different tandem  
541 carbohydrate-recognition domains. *FEBS Lett.* 443: 139-143.
- 542 **60.** Watanabe, A., S. Miyazawa, M. Kitami, H. Tabunoki, K. Ueda, and R. Sato. 2006.  
543 Characterization of a novel C-type lectin, *Bombyx mori* multibinding protein, from the *B. mori*  
544 hemolymph: mechanism of wide-range microorganism recognition and role in immunity. *J.*  
545 *Immunol.* 177: 4594-4604.
- 546 **61.** Chen, C., A. F. Rowley, R. P. Newton, N. A. Ratcliffe. 1999. Identification, purification and  
547 properties of a beta-1,3-glucan-specific lectin from the serum of the cockroach, *Blaberus*  
548 *discoidealis* which is implicated in immune defence reactions. *Comp. Biochem. Physiol. B*  
549 *Biochem. Mol. Biol.* 122: 309-319.
- 550 **62.** Browne, N., M. Heelan, and K. Kavanagh. 2013. An analysis of the structural and functional  
551 similarities of insect hemocytes and mammalian phagocytes. *Virulence.* 4: 597-603.
- 552 **63.** Means T. K., E. Mylonakis, E. Tampakakis, R. A. Colvin, E. Seung, L. Puckett, M. F. Tai, C.  
553 R. Stewart, R. Pukkila-Worley, S. E. Hickman, K. J. Moore, S. B. Calderwood, N. Hacohen, A.  
554 D. Luster, and J. El Khoury. 2009. Evolutionarily conserved recognition and innate immunity to  
555 fungal pathogens by the scavenger receptors SCARF1 and CD36. *J. Exp. Med.* 206: 637-653.
- 556 **64.** Gross, O., A. Gewies, K. Finger, M. Schäfer, T. Sparwasser, C. Peschel, I. Förster, and J.  
557 Ruland. 2006. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.  
558 *Nature.* 442: 651-656.



- 559       **65.** Goodridge, H. S., R. M. Simmons, and D. M. Underhill. 2007. Dectin-1 stimulation by *Candida*  
560       albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. *J.*  
561       *Immunol.* 178: 3107-3115.
- 562       **66.** LeibundGut-Landmann, S., O. Gross, M. J. Robinson, F. Osorio, E. C. Slack, S. V. Tsoni, E.  
563       Schweighoffer, V. Tybulewicz, G. D. Brown, J. Ruland, and C. Reis e Sousa. 2007. Syk- and  
564       CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce  
565       interleukin 17. *Nat. Immunol.* 8:630-638.

566

## 567 **FIGURE LEGENDS**

568 **FIGURE 1.** Mannose receptor is important but dispensable during uptake of *Cryptococcus* particles.

569 Mouse macrophage cell line J774.A1 (A) or differentiated bone marrow macrophages (B, wildtype,  
570 WT or mannose receptor knock out, MR KO) or differentiated primary human macrophages (C) were  
571 challenged with either *Cryptococcus neoformans* H99 (Cn, black bars) or *Cryptococcus gattii* R265  
572 (Cg, white bars) for 60min, processed for immunofluorescence and scored for phagocytosis as  
573 described in Materials and Methods. Where indicated, J774.A1 and primary human macrophages were  
574 pretreated with 100µg/ml mannan (MAN) for 30min before the addition of *Cryptococcus* particles.  
575 Phagocytosis indices were related to the values obtained from the negative controls. Number in bars  
576 indicate the total number of phagocytes counted. Results are expressed as the mean± SD of at least  
577 three independent experiments.

578

579 **FIGURE 2:** Uptake of *Cryptococcus* particles is Syk dependent. Mouse macrophage cell line J774.A1  
580 (A) or differentiated primary human macrophages (B) were challenged with unopsonised *Cryptococcus*  
581 *neoformans* H99 (Cn, black bars) or *Cryptococcus gattii* R265 (Cg, white bars) for 60 min, processed  
582 for immunofluorescence and scored for phagocytosis as described in Materials and Methods.  
583 Phagocytosis indices were related to the values obtained from the negative controls. Number in bars

584 indicate the total number of phagocytes counted. Results are expressed as the mean± SD of at least  
585 three independent experiments.

586

587 **FIGURE 3.** Activated Syk is essential for the uptake of *Cryptococcus* particles. Mouse macrophage  
588 cell line J774.A1 was challenged with either (IgG-opsonised or unopsonised, U/O) *Cryptococcus*  
589 *neoformans* H99 or *Cryptococcus gattii* R265 for 15min (B), processed for immunofluorescence and  
590 analysed by confocal microscopy of localised phospho-Syk (B, C) as described in Materials and  
591 Methods. (A) Schematic diagram J774.A1 macrophage with intracellular actin cytoskeleton (red) and  
592 yeast particles (blue). To confirm phospho-Syk localisation, the bottom of the cells was observed first  
593 (A, green dash line and B, bottom panels), before moving to the middle of the cells (A, purple dash  
594 line, B, top panels). Pixel intensities for 20 cells per sample were determined (C, right) and normalised  
595 to the intensity at the centre of the cell (C, left). Results are expressed as the mean± SD of at least three  
596 independent experiments.

597

598 **FIGURE 4.** Dectins are required for uptake of *Cryptococcus* particles. Mouse macrophage cell line  
599 J774.A1 (A), differentiated primary human macrophages (B) or differentiated bone marrow  
600 macrophages (C, wildtype, WT or Dectin-1 or Dectin-2 knockout, KO) were challenged with either  
601 *Cryptococcus neoformans* H99 (Cn, black bars) or *Cryptococcus gattii* R265 (Cg, white bars) for 60  
602 min, processed for immunofluorescence and scored for phagocytosis as described in Materials and  
603 Methods. Where indicated, J774.A1 were pretreated with 100µg/ml glucan-6-phosphate (G6P) for  
604 30min before the addition of *Cryptococcus* particles. Phagocytosis indices were related to the values  
605 obtained from the negative controls. Number in bars indicate the total number of phagocytes counted.  
606 Results are expressed as the mean± SD of at least three independent experiments. ns, not significant,  $p$   
607  $\geq 0.05$ ; \*,  $p < 0.05$

608

609 **FIGURE 5.** Administration of polysaccharides blocks uptake of *Cryptococcus* particles to hemocytes  
610 in the *Galleria mellonella* larvae model. Larvae were inoculated with 60µg of blocking sugars 1hr  
611 prior to infection for 2hr with 10<sup>6</sup> *Cryptococcus neoformans* H99 (black bars) or *Cryptococcus gattii*  
612 R265 (white bars). Uptake of yeast of hemocytes was determined under light microscopy. Results are  
613 expressed as the mean± SD of at least three independent experiments. ns, not significant,  $p \geq 0.05$ ; \*,  $p$   
614 < 0.05 (related to PBS control)

615  
616 **FIGURE 6.** Glucan administration protects *Galleria mellonella* larvae from infection by *Cryptococcus*  
617 *neoformans* or *Cryptococcus gattii*. Larvae were inoculated with 60µg of blocking sugars 24hr prior to  
618 infection for further 24hr with 10<sup>6</sup> *Cryptococcus neoformans* H99 (black bars) or *Cryptococcus gattii*  
619 R265 (white bars). Fungal load was determined by serially diluting homogenized larvae and plating  
620 aliquots onto erythromycin containing agar plates. Yeast cell density were related to the values  
621 obtained from the negative (PBS) controls and expressed as cfu \*10<sup>5</sup>/larva. Results are expressed as the  
622 mean ± SD of at least three independent experiments. ns, not significant,  $p \geq 0.05$ ; \*,  $p < 0.05$  (related  
623 to PBS control)




624  
625 **FIGURE 7.** Uptake of *Cryptococcus* did not affect NFκB nuclear translocation. J774.A1 macrophages  
626 were challenged with a variety of opsonised or unopsonised pathogenic fungi or sheep red blood cells  
627 (SRBC) or soluble agonists (LPS or PMA), processed for immunofluorescences and analysed by  
628 microscopy (A) and scored for p65 nuclear translocation (B), as described in Materials and Methods.  
629 (A) Representative images of PMA- (top) or LPS- (bottom) stimulated J774.A1 macrophages and  
630 stained to highlight either actin or p65. Bar, 20µm.

631

632 **FIGURE 8.** Uptake of *Cryptococcus* did not affect proinflammatory cytokine response. J774.A1  
633 macrophages (**black bars**) or differentiated primary human macrophages (**white bars**) were challenged  
634 with a variety of unopsonised pathogenic fungi (*Cryptococcus neoformans*, Cn; *Cryptococcus gattii*,  
635 Cg; *Candida albicans*, Ca) or LPS and subsequent supernatants were analysed by ELISA, as described  
636 in Materials and Methods. Results are expressed as the mean  $\pm$  SD of at least three independent  
637 experiments. \*,  $p < 0.05$


638

For Peer Review. Do not distribute. Destroy after use.




**A (J774.A1)**





■ Cn □ Cg





**B (Human)**

■ Cn □ Cg





**A****B****C**